| The epidemiology of lung cancer |
93 |
| Methods of measurement for tumor mutational burden in tumor tissue |
40 |
| Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians |
30 |
| The clinical utility of tumor mutational burden in non-small cell lung cancer |
29 |
| Current standards for clinical management of small cell lung cancer |
28 |
| Tobacco and the lung cancer epidemic in China |
25 |
| Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes |
22 |
| Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience |
18 |
| Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition) |
17 |
| Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms |
16 |
| Targeting DNA damage repair in small cell lung cancer and the biomarker landscape |
15 |
| Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis |
14 |
| Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward |
14 |
| Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy |
13 |
| Lung cancer in never smokers-the East Asian experience |
13 |
| EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing |
12 |
| Long-term survival outcomes of video-assisted thoracic surgery lobectomy for stage I-II non-small cell lung cancer are more favorable than thoracotomy: a propensity score-matched analysis from a high-volume center in China |
12 |
| Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment |
12 |
| A scalable solution for tumor mutational burden from formalinfixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay |
11 |
| Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? |
11 |
| Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights |
11 |
| Lung cancer screening with low-dose CT: a world-wide view |
11 |
| Update on the management of malignant peritoneal mesothelioma |
11 |
| Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI) |
11 |
| Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey |
11 |
| A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial |
11 |
| Selecting lung cancer screenees using risk prediction models where do we go from here |
10 |
| Blood based biomarkers beyond genomics for lung cancer screening |
10 |
| What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era? |
10 |
| Environmental and occupational determinants of lung cancer |
10 |
| Stereotactic body radiotherapy as salvage treatment for recurrence of non-small cell lung cancer after prior surgery or radiotherapy |
10 |
| Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy |
10 |
| Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we? |
9 |
| Shared decision-making conversations and smoking cessation interventions: critical components of low-dose CT lung cancer screening programs |
9 |
| EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases |
9 |
| Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy |
9 |
| Extracellular vesicle-based EGFR genotyping in bronchoalveolar lavage fluid from treatment-naive non-small cell lung cancer patients |
9 |
| Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree? |
9 |
| Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review |
9 |
| Malignant peritoneal mesothelioma: a review |
8 |
| The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures |
8 |
| Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: a population-based study |
8 |
| Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma |
8 |
| The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 383 patients |
8 |
| Advanced Proton Beam Dosimetry Part I: review and performance evaluation of dose calculation algorithms |
8 |
| Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer |
8 |
| The evolving toxicity profile of SBRT for lung cancer |
8 |
| Tobacco smoking after diagnosis of cancer: clinical aspects |
8 |
| Combining stereotactic body radiation therapy with immunotherapy: current data and future directions |
8 |
| Approach to evaluating tumor mutational burden in routine clinical practice |
8 |
